Orexigen Therapeutics Inc. (OREX) said that the FDA advisory committee will review the company's new drug application for Contrave for the treatment of obesity on December 7, 2010.
The FDA has already set January 31, 2011 as the Prescription Drug User Fee Act action date for Contrave.
Contrave is an investigational combination therapy believed to address both physiological and behavioral drivers of obesity.
In clinical trials, Contrave was shown to help obese patients initiate and sustain significant weight loss, improve important markers of cardiometabolic risk and increase ability to control eating.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.